Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and

  Galectin Therapeutics Receives US Patent for Second Drug Class to Treat
  Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis

Business Wire

NORCROSS, Ga. -- November 26, 2012

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics
that target galectin proteins to treat fibrosis and cancer, today announced
that it has received a notice of allowance from the U.S. Patent and Trademark
Office for a divisional patent of Patent Number 8,236,780 “Galactose-prolonged
polysaccharides in a formulation for antifibrotic therapies”. The patent
covers key methods of derivation and use for the Company’s galactomannan-based
carbohydrate galectin inhibitor compounds, for use in patients with chronic
liver disease associated with the development of fibrosis, established liver
fibrosis or end-stage scarring, or cirrhosis. Fibrotic disease of the liver is
highly prevalent in the population because all chronic liver diseases,
including viral hepatitis, fatty liver and alcohol abuse, result in fibrosis
of the liver for which there are no currently approved pharmaceutical
therapies.

“This patent broadens Galectin Therapeutics’ intellectual property to include
two distinct classes of galectin inhibitors for the treatment of liver
fibrosis, a highly prevalent and critical medical condition with no approved
treatments other than transplantation,” said Peter G. Traber, MD, President,
CEO and CMO of Galectin Therapeutics. “The intellectual property protection
for our galactomannan (GM)-based compounds augments our IP portfolio, which
already contains coverage for galacto-rhamnogalacturonan (GR)-based compounds,
thus enabling a pipeline of candidates with drugs from each class that can be
evaluated for the treatment of fibrosis.”

“GM-CT-01, our first galactomannan-based compound, has demonstrated an
excellent safety profile in over 100 patients and could be moved rapidly
forward in Phase 2 clinical trials in fibrosis,” commented Traber. “GM-CT-01
could be useful as a follow-on compound to GR-MD-02, our lead clinical
compound in fibrosis, for stand-alone or combination therapeutic approaches.
Preclinical results of both our GM- and GR-based candidates have shown
reversal of fibrosis in rodent models of disease.”

The major claim is for a method of obtaining the galectin inhibitor compound,
obtaining a composition for parenteral administration in an acceptable
pharmaceutical carrier and administering to a subject having at least one of
the following: chronic liver disease associated with the development of
fibrosis, established liver fibrosis or cirrhosis. The use covers inhibiting
or slowing the progression of fibrosis or the reversal of fibrosis.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.

Contact:

Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
ir@galectintherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.